In late November Abbott—one of Dexcom’s main competitors— recalled some of its CGMs due to inaccurate low glucose readings.

Dexcom has issued a Class I recall for its G6 glucose sensor Android application due to a defect that causes the app to crash unexpectedly. As a result of the app terminating, users could miss ...

DexCom (DXCM) is under the spotlight after several class action lawsuits were filed claiming the company made unauthorized changes to its G6 and G7 glucose monitoring devices. These changes could ...

Shares of medical device company DexCom (NASDAQ:DXCM) jumped 3.7% in the afternoon session after it rebounded from a steep sell-off that was triggered by its long-term revenue growth outlook. The ...

Shares have lagged the market this year, partly due to some public image and regulatory issues. DexCom's stock could drop even more if results falls short of revenue expectations. Whatever happens on ...

A recent investigation by Hunterbrook alleged that Dexcom "dropped the ball" in ensuring the accuracy and reliability of its G7 glucose monitoring device. Some patients reportedly experienced severe ...

People with Type 1 diabetes are estimated to make up to 180 more decisions a day than someone without the disease, according to a study from Stanford University. Each meal, workout, or night’s sleep ...

Shares of DexCom (NASDAQ:DXCM) fell for the third straight session on Friday to reach the lowest level since April, even as the continuous glucose monitoring (CGM) equipment maker managed to retain ...

Dexcom is recalling 19 models of its continuous glucose monitoring receivers due to a speaker malfunction that could prevent alerts for dangerous blood sugar levels. The affected devices are models ...

Dexcom has recalled its G6, G7, ONE, and ONE+ continuous glucose monitor (CGM)receivers due to a speaker malfunction that could cause missed low or high blood sugar alerts. The recall, for which ...

Sometimes the best way to fix a mistake is to double down on it—and that is just what DexCom is doing with its continuous glucose monitors for diabetes patients. It’s a decision that should pay off ...

The Food and Drug Administration (FDA) has cleared diabetes-management firm DexCom's (DXCM) new continuous glucose monitoring (CGM) system. The San Diego, Calif.-based firm said Thursday that its ...